AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Nuwellis, Inc. Common Stock
XNAS · usd
SIC 3845 · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
FIGI BBG001SNT6T0
0.32▼ 0.17 (-33.97%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.49
Day's Range
0.32 – 0.49
52-Week Range
0.08 – 6.40
Volume
591.0K
Avg Volume
2.2M
Share Statistics
Shares Outstanding
Employees
38
Exchange
XNAS
Listed
2012-02-16
Share count as of August 10, 2026

Nuwellis, Inc. Common Stock (NUWE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Nuwellis, Inc. Common Stock (NUWE)
What is Nuwellis, Inc. Common Stock's Market Cap?
Nuwellis, Inc. Common Stock's Market Cap is $1.2M, based on as-reported figures from SEC (XBRL) filings.
What is Nuwellis, Inc. Common Stock's Enterprise Value?
Nuwellis, Inc. Common Stock's Enterprise Value is -$2.7M, based on as-reported figures from SEC (XBRL) filings.
What is Nuwellis, Inc. Common Stock's Net Debt?
Nuwellis, Inc. Common Stock's Net Debt is -$3.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · NUWEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Net sales
YoY growth+14.1%+26.2%+4.4%-6.3%
Cost of goods sold
Gross profit
% of revenue76.1%70.1%68.2%65.2%
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
% of revenue237.0%260.2%169.0%186.8%
Loss from operations
% of revenue-160.9%-190.1%-100.8%-121.7%
Other income
Financing expense—
Change in fair value of warrant liabilities
Loss before income taxes
Income tax expense
Net loss
% of revenue-245.2%-189.0%-99.9%21.1%
Deemed dividend attributable to Series J Convertible Preferred Stock
Net loss attributable to common shareholders
Basic loss per share (in Dollars per share)—
Diluted loss per share (in Dollars per share)—